Comparison of atrial natriuretic peptide, B-type natriuretic peptide, and N-terminal proatrial natriuretic peptide as indicators of left ventricular systolic dysfunction

Davidson, Neil C.; Naas, Abdelwahab A.; Hanson, Jacqueline; Kennedy, Norman; Coutie, Wendy J.; Struthers, Allan D.

doi:10.1016/s0002-9149(97)89176-x

Cited by 177 publications

(97 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Tested by a ROC curve, the diagnostic capacities of NT-proBNP were better compared to ANP, and no additional information was obtained by combining NT-proBNP with ANP. Similar to our findings, in earlier studies with a direct comparison between atrial and brain natriuretic peptides, an advantage for brain natriuretic peptides was convincingly proved with no increased predictive power by addition of ANP to BNP determination (Davidson et al, 1996;Cowie et al, 1997;McDonagh et al, 1998;Hammerer-Lercher et al, 2001). Natriuretic peptides are mainly produced and excreted in the atria of the heart in response to increased wall tension.…”

Section: Discussionsupporting

confidence: 91%

“…In patients with the suspicion of heart failure several other studies showed natriuretic peptides to be useful indicators for the detection of heart failure (Lerman et al, 1993;Davidson et al, 1996;Cowie et al, 1997;Hammerer-Lercher et al, 2001;Maisel et al, 2002Maisel et al, , 2003. In the follow-up of patients with an acute cardiac event levels of natriuretic peptides were proved to be of prognostic value for outcome (Hall et al, 1994;Omland et al, 1996;de Lemos et al, 2001;Koglin et al, 2001;Richards et al, 2003).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Role of natriuretic peptides in the diagnosis and treatment of patients with carcinoid heart disease

et al. 2004

View full text Add to dashboard Cite

Carcinoid heart disease (CHD) occurs in 20 -70% of the patients with metastatic well-differentiated neuroendocrine tumours (NET). We evaluated whether natriuretic peptides (ANP or NT-proBNP) are useful in early detection of CHD. Blood samples from 32 patients with NET were compared with cardiac ultrasound follow-up. CHD was defined as thickening of the tricuspid valve in the presence of grade III -IV/IV tricuspid valve regurgitation. CHD was found in nine out of 32 patients (28%), all with symptoms of the carcinoid syndrome compared to 65% in the 23 patients without CHD (P ¼ 0.04). Median levels of NT-proBNP and 5-HIAA were significantly higher in patients with CHD (894 ng l À1 and 815 mmol 24 h À1 ) compared to those without (89 and 206 ng l À1 , Po0.001 and P ¼ 0.007). No significant differences were detected in ANP levels (P ¼ 0.11). Dilatation of the right atrium and ventricle as well as thickening of the tricuspid valve and degree of regurgitation were statistically significant correlated with NT-proBNP levels. The accuracy of NT-proBNP in the diagnosis of CHD was higher than that of ANP. A significantly better survival was observed in case of normal NT-proBNP values. In conclusion, NT-proBNP is helpful as a simple marker in the diagnosis of CHD. Survival is better in patients with normal levels of NT-proBNP.

show abstract

Section: Discussionsupporting

confidence: 91%

mentioning

confidence: 99%

Role of natriuretic peptides in the diagnosis and treatment of patients with carcinoid heart disease

et al. 2004

View full text Add to dashboard Cite

show abstract

“…Furthermore, increased natriuretic peptide levels have been related to decreased left ventricular ejection fraction (LVEF) values in patients with left ventricular dysfunction or coronary artery disease [15]. As a consequence, elevated natriuretic peptide values are considered to be indicative of left ventricular dysfunction.…”

mentioning

confidence: 99%

Circulating apoptotic proteins are increased in long-term disease-free breast cancer survivors

et al. 2006

View full text Add to dashboard Cite

“…11 The plasma levels of both peptides are inversely correlated with measures of cardiac function 9 and recent work has shown BNP to be a more sensitive marker of cardiac impairment than ANP. 12,13 Indeed, plasma BNP levels are useful in differentiating acute heart failure from pulmonary disease 14 and for the early diagnosis of heart failure. 15 The aims of this study were to investigate plasma BNP as a marker of ventricular dysfunction in patients receiving high-dose preparative regimens and HSCT.…”

mentioning

confidence: 99%

Assessment of cardiotoxicity during haemopoietic stem cell transplantation with plasma brain natriuretic peptide

Snowden

Hill

Hunt

et al. 2000

Bone Marrow Transplant

View full text Add to dashboard Cite

Summary:Cardiac failure is a known complication of haemopoietic stem cell transplantation (HSCT) and is often difficult to diagnose as patients may have multiple medical problems. Since brain natriuretic peptide (BNP) is largely a hormone of cardiac ventricular origin and is released early in the course of ventricular dysfunction, we have examined the value of serial plasma BNP levels for detecting cardiac failure in patients undergoing cytotoxic conditioning for HSCT. Fifteen patients undergoing HSCT were evaluated (10 undergoing autologous HSCT; five undergoing allogeneic HSCT). BNP was measured by radioimmunoassay prior to therapy and weekly for 5 weeks. Seven patients had a significant rise in BNP level (above a previously established threshold of 43 pmol/l associated with cardiac failure), occurring 1-4 weeks post commencement of conditioning. In three of these patients, cardiac failure was subsequently diagnosed clinically 3, 9 and 23 days after a BNP level of 43 pmol/l had been detected. These three patients had the highest peak BNP levels for the group and in each case elevation in BNP level occurred for a period exceeding 1 week. Although numbers were relatively small, a BNP Ͼ43 pmol/l was significantly associated with the inclusion of high-dose cyclophosphamide in the preparative regimen (P = 0.02). BNP levels showed no relationship to febrile episodes. In conclusion, these results show that plasma BNP may be used as a marker for early detection of cardiac dysfunction in patients undergoing HSCT, particularly if levels are increased for periods exceeding 1 week. Measurement of BNP during HSCT may be helpful in patients at risk of cardiac failure, in complex clinical situations and in monitoring the cardiotoxicity of preparative regimens. Bone Marrow Transplantation (2000) 26, 309-313.

show abstract

Comparison of atrial natriuretic peptide, B-type natriuretic peptide, and N-terminal proatrial natriuretic peptide as indicators of left ventricular systolic dysfunction

Cited by 177 publications

References 5 publications

Role of natriuretic peptides in the diagnosis and treatment of patients with carcinoid heart disease

Role of natriuretic peptides in the diagnosis and treatment of patients with carcinoid heart disease

Circulating apoptotic proteins are increased in long-term disease-free breast cancer survivors

Assessment of cardiotoxicity during haemopoietic stem cell transplantation with plasma brain natriuretic peptide

Contact Info

Product

Resources

About